Selective inhibition of JAK1 with filgotinib reverses pathogenic processes in the DSS preclinical model for IBD
Ontology highlight
ABSTRACT: The pathogenesis of inflammatory bowel diseases (IBD) is associated with a dysregulated mucosal immune response. The signaling of several cytokines regulating this immune response is mediated by kinases of the JAK family, i.e. JAK1, JAK2, JAK3 and TYK2. Filgotinib is a JAK1-selective inhibitor with demonstrated efficacy in phase 2 trials in patients with rheumatoid arthritis (RA) and Crohn’s disease (CD). Here, we investigated the effects of filgotinib on the DSS (dextran sulfate sodium) mouse model
ORGANISM(S): Mus musculus
PROVIDER: GSE105417 | GEO | 2020/10/19
REPOSITORIES: GEO
ACCESS DATA